New Drug ION224 Shows Promise in Reversing Severe Liver Disease
A new drug called ION224 could offer hope for people suffering from metabolic dysfunction-associated steatohepatitis (MASH). Researchers at the University of California San Diego have found that the treatment reduces liver fat and inflammation, two key causes of liver damage in the condition. Early trials suggest it may become the first targeted therapy to halt or even reverse progression in some patients.
MASH, also known as nonalcoholic steatohepatitis (NASH), is a severe form of fatty liver disease linked to metabolic conditions like obesity and type 2 diabetes. Without treatment, it can lead to liver failure. Over 100 million people in the U.S. and up to one in four adults globally may have some form of fatty liver disease.
ION224 works by blocking an enzyme called DGAT2, which helps control fat production and storage in the liver. In a Phase IIb clinical trial, 60% of participants on the highest dose showed significant liver health improvements compared to those on a placebo. Notably, these benefits occurred even without weight loss, meaning the drug could complement other treatments.
The trial also reported no serious side effects tied to the drug. While these results are promising, ION224 has not yet entered Phase III testing, which would be needed before approval. If successful, it could become the first therapy specifically designed to stop and potentially reverse liver damage in MASH patients.
The development of ION224 marks a potential breakthrough in treating MASH, a condition with limited treatment options. If confirmed in further trials, the drug could ease pressure on healthcare systems by reducing the need for advanced liver disease interventions. For now, researchers continue to monitor its progress toward wider approval.
